Post-retirement enlightenment syndrome: Worthy of investigation.

Drug policy reform Harm reduction Political courage Political will Politicians

Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 09 03 2023
revised: 01 05 2023
accepted: 02 05 2023
medline: 26 6 2023
pubmed: 17 5 2023
entrez: 17 5 2023
Statut: ppublish

Résumé

Post-Retirement Enlightenment Syndrome is a term used by some in illicit drug policy to reflect the experience of having politicians "come out" in favour of drug policy reform only after retirement. To date, the phenomenon has not been examined in any systematic manner. While discussions of the phenomenon on social media tend to be playful, they nevertheless express real frustration with the reluctance of privately supportive sitting politicians and policing officials to speak out in favour of non-punitive and/or harm reduction-oriented policies. In this commentary, we give an overview of the phenomenon of Post-Retirement Enlightenment Syndrome. We argue that these instances of sitting officials speaking out publicly in favour of drug policy reform, as well as instances in which such apparent "enlightenment" is not publicly expressed until after retirement, are potentially highly fruitful areas for investigation. Public positions on drug policy are invariably contoured by conditions of political possibility. We raise the call for both an unpacking and examination of the structural and relational aspects of "political will" and "political courage". Sitting and retired politicians each have a role in the drug policy landscape, whether as lawmakers or as high-profile and often respected commentators. This commentary argues that a more nuanced understanding of the conditions that may support or hinder the expression of public support for drug policy reform by political office bearers, whether sitting or former, has implications for advocates and researchers invested in policy change.

Identifiants

pubmed: 37196378
pii: S0955-3959(23)00107-X
doi: 10.1016/j.drugpo.2023.104059
pii:
doi:

Substances chimiques

Illicit Drugs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104059

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Laura McLauchlan (L)

Drug Policy Modelling Program, UNSW, Australia.

Paul Kelaita (P)

Drug Policy Modelling Program, UNSW, Australia.

Michala Kowalski (M)

Drug Policy Modelling Program, UNSW, Australia.

Alison Ritter (A)

Drug Policy Modelling Program, UNSW, Australia. Electronic address: alison.ritter@unsw.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH